DUKE UNIVERSITY HOSPITAL
- Type
- Teaching hospital
- Where
- Durham, NC
- Medicare CCN
- 340030
- Received
- $33,467,371 in 973 records, 2019 ($1,696,023 general, $31,771,348 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 243 | $1,696,023 |
| 2019 | Research payment | 730 | $31,771,348 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 730 | $31,771,348 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 52 | $1,219,049 |
| Education | 17 | $180,408 |
| Space rental or facility fees (teaching hospital only) | 52 | $135,350 |
| Gift | 23 | $75,449 |
| Grant | 11 | $60,382 |
| Royalty or License | 74 | $14,798 |
| Charitable Contribution | 5 | $6,396 |
| Consulting Fee | 3 | $2,960 |
| Travel and Lodging | 3 | $1,008 |
| Food and Beverage | 3 | $220 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | AngioDynamics, Inc. | $60,000 | Education | In-kind items and services | Nanoknife Device, Oncology Surgery | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $52,320 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | HEARTFLOW, INC. | $27,442 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-12-31 | Stryker Corporation | $16,262 | Gift | In-kind items and services | NSE - SONOPET Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Intuitive Surgical, Inc. | $10,720 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-12-31 | Stryker Corporation | $8,484 | Gift | In-kind items and services | NSE - SONOPET Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $5,457 | Gift | Cash or cash equivalent | NONE Device, NONE | 2019 | |
| 2019-12-31 | Stryker Corporation | $4,809 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $4,269 | Gift | In-kind items and services | NSE - HIGH SPEED DRILLS Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $3,473 | Gift | In-kind items and services | NSE - BONE MILL Device, NEURO SPINE ENT | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,638 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,638 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | bioMerieux Inc | $2,452 | Research payment | In-kind items and services | VIDAS BRAHMS PCT Device, Diagnostic | Use of Host-Based Diagnostics to Improve Antimicrobial Stewardship in Resource-Limited Settings | 2019 |
| 2019-12-31 | Stryker Corporation | $2,403 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | Stryker Corporation | $2,101 | Gift | In-kind items and services | SURG - REMB Device, SURGICAL | 2019 | |
| 2019-12-31 | PENTAX of America, Inc. | $249 | Gift (2 payments) | In-kind items and services | Device, Gastroenterology | 2019 | |
| 2019-12-30 | TransMedics, Inc. | $24,452 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | EXPAND HEART CAP | 2019 |
| 2019-12-30 | TransMedics, Inc. | $21,679 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | EXPAND HEART CAP | 2019 |
| 2019-12-30 | TerSera Therapeutics LLC | $12,588 | Research payment | Cash or cash equivalent | VARUBI Drug, ONCOLOGY | Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapita | 2019 |
| 2019-12-30 | TransMedics, Inc. | $4,000 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS LUNG TOP PAS REGISTRY | 2019 |
| 2019-12-30 | TransMedics, Inc. | $1,509 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS LUNG TOP REGISTRY | 2019 |
| 2019-12-29 | AstraZeneca Pharmaceuticals LP | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-12-27 | Vascular Graft Solutions Inc | $47,027 | Research payment | Cash or cash equivalent | VEST Device | VEST Venous Graft External Support Pivotal Study | 2019 |
| 2019-12-21 | CSL Behring | $607,868 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-12-19 | TransMedics, Inc. | $4,000 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS LUNG TOP REGISTRY | 2019 |
| 2019-12-19 | Agios Pharmaceuticals, Inc. | $2,952 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-12-19 | EXACTECH, INC. | $1,818 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2019 | |
| 2019-12-19 | INSTRUMENTATION LABORATORY COMPANY | $1,000 | Research payment | Cash or cash equivalent | ACL TOP Clinical Device | 2019 | |
| 2019-12-19 | INSTRUMENTATION LABORATORY COMPANY | $1,000 | Research payment | Cash or cash equivalent | ACL TOP Clinical Device | 2019 | |
| 2019-12-18 | CSL Behring | $20,800 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-12-18 | Travere Therapeutics, Inc. | $984 | Research payment | Cash or cash equivalent | (810) Chenodal Drug, Hepatology | 018CTXX15001 | 2019 |
| 2019-12-18 | CSL Behring | $189 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-12-18 | CSL Behring | $161 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-12-17 | Dompe US, Inc. | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-16 | Purdue Pharma L.P. | $15,930 | Research payment | Cash or cash equivalent | ADHANSIA XR Drug, PRESCRIPTION STIMULANT | 063-020 | 2019 |
| 2019-12-16 | Purdue Pharma L.P. | $11,328 | Research payment | Cash or cash equivalent | ADHANSIA XR Drug, PRESCRIPTION STIMULANT | 063-020 | 2019 |
| 2019-12-16 | Merck Sharp & Dohme LLC | $1,028 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2019 |
| 2019-12-16 | Purdue Pharma L.P. | $960 | Research payment | Cash or cash equivalent | ADHANSIA XR Drug, PRESCRIPTION STIMULANT | 063-020 | 2019 |
| 2019-12-15 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | IMFINZI Drug, Oncology | 2019 | |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $4,838 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $2,283 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto- | 2019 |
| 2019-12-13 | W. L. Gore & Associates, Inc. | $768 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore Research and Development | 2019 |
| 2019-12-12 | Stemline Therapeutics Inc. | $5,550 | Research payment | Cash or cash equivalent | STML-401-0114 | 2019 | |
| 2019-12-12 | CSL Behring | $2,777 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-12 | CSL Behring | $1,783 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-12 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-11 | CSL Behring | $17,169 | Research payment | Cash or cash equivalent | Variability of Cryoprecipitate Content Research - CSL Switzerland | 2019 | |
| 2019-12-11 | ACUMED LLC | $3,150 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Hand Fracture System Device, Hand & Wrist | 2019 | |
| 2019-12-10 | Agios Pharmaceuticals, Inc. | $1,675 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-12-09 | Purdue Pharma L.P. | $6,451 | Research payment | Cash or cash equivalent | ADHANSIA XR Drug, PRESCRIPTION STIMULANT | 063-020 | 2019 |
| 2019-12-08 | AstraZeneca Pharmaceuticals LP | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CALQUENCE Drug, Oncology | 2019 | |
| 2019-12-06 | HEARTFLOW, INC. | $24,913 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-12-06 | HEARTFLOW, INC. | $19,580 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-12-05 | Leadiant Biosciences, Inc. | $30,568 | Research payment | Cash or cash equivalent | Revcovi Biological, Immunodeficiency | Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | 2019 |
| 2019-12-05 | CSL Behring | $21,513 | Research payment | Cash or cash equivalent | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 | |
| 2019-12-05 | EXACTECH, INC. | $1,818 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2019 | |
| 2019-12-05 | CSL Behring | $273 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-05 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-12-04 | CSL Behring | $26,000 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-12-04 | Merck Sharp & Dohme LLC | $13,700 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma | 2019 |
| 2019-12-03 | CSL Behring | $1,341,432 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-12-03 | Amicus Therapeutics, Inc. | $14,472 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2019 | |
| 2019-12-03 | Bolton Medical Inc | $610 | Research payment | Cash or cash equivalent | Relay PAS Device | Relay PAS | 2019 |
| 2019-12-02 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2019 | |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $26 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-02 | Boehringer Ingelheim International GmbH | $20 | Research payment | In-kind items and services | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-12-01 | Pacira Therapeutics, Inc. | $186,123 | Research payment | Cash or cash equivalent | Zilretta Drug, Musculoskeletal | An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients with Oste | 2019 |
| 2019-11-29 | Laminate Medical Technologies inc. | $4,375 | Research payment | Cash or cash equivalent | Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2019 |
| 2019-11-27 | Merck Sharp & Dohme LLC | $7,988 | Research payment | Cash or cash equivalent | RECARBRIO Drug, INFECTIOUS DISEASE | A Phase 1b, Open label, Single dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Chil | 2019 |
| 2019-11-27 | Purdue Pharma L.P. | $5,897 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | OXYCONTIN Drug, PAIN MANAGEMENT | 2019 | |
| 2019-11-26 | Agios Pharmaceuticals, Inc. | $2,952 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-11-25 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2019 |
| 2019-11-25 | KARL STORZ Endoscopy-America | $596 | Gift | In-kind items and services | 7 FLAT PANEL MONITOR ONLY F/C-MAC, HDMI Device, ANESTHESIOLOGY | 2019 | |
| 2019-11-22 | Merck Sharp & Dohme LLC | $5,488 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-11-22 | Merck Sharp & Dohme LLC | $1,594 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $303 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | Cardiovascular Systems Inc. | $287 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $117 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-19 | Baxter Healthcare | $59,876 | Research payment | Cash or cash equivalent | IPS - Nutrition Biological, Integrated Pharmacy Solutions | Longitudinal Evaluation of Energy Expenditure in ICU Patients from Admission to Discharge using a Novel Indirect Calorim | 2019 |
| 2019-11-18 | Bolton Medical Inc | $16,564 | Research payment | Cash or cash equivalent | Relay Arch-EFS Device | Relay Arch-EFS | 2019 |
| 2019-11-18 | AstraZeneca Pharmaceuticals LP | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-11-15 | W. L. Gore & Associates, Inc. | $750 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2019 |
| 2019-11-14 | EXACTECH, INC. | $4,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VANTAGE Device, ORTHOPAEDIC | 2019 | |
| 2019-11-14 | TriMed, Inc. | $1,350 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-11-14 | Agios Pharmaceuticals, Inc. | $1,086 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-11-14 | FUJIFILM SonoSite, Inc. | $194 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2019 | |
| 2019-11-14 | Stemline Therapeutics Inc. | $168 | Research payment | Cash or cash equivalent | STML-401-0114 | 2019 | |
| 2019-11-13 | Boehringer Ingelheim International GmbH | $90,000 | Research payment | Cash or cash equivalent | Empagliflozin and Heart failure | 2019 | |
| 2019-11-13 | Merck Sharp & Dohme LLC | $4,025 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2019 |
| 2019-11-13 | Merck Sharp & Dohme LLC | $655 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2019 |
| 2019-11-13 | Merck Sharp & Dohme LLC | $282 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2019 |
| 2019-11-12 | CSL Behring | $22,360 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-11-12 | CSL Behring | $8,301 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-11-12 | AstraZeneca Pharmaceuticals LP | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-11-12 | Agios Pharmaceuticals, Inc. | $1,202 | Research payment | Cash or cash equivalent | PyruvateKinase Deficiency Global Longitudinal Registry | 2019 | |
| 2019-11-12 | Agios Pharmaceuticals, Inc. | $40 | Research payment | Cash or cash equivalent | PyruvateKinase Deficiency Global Longitudinal Registry | 2019 | |
| 2019-11-07 | CSL Behring | $12,239 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | Agios Pharmaceuticals, Inc. | $11,269 | Research payment | Cash or cash equivalent | AG348-C-011 | 2019 | |
| 2019-11-07 | CSL Behring | $782 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-07 | CSL Behring | $50 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-11-06 | HEARTFLOW, INC. | $38,636 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-11-06 | Dova Pharmaceuticals | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Doptelet Drug, Hepatology | 2019 | |
| 2019-11-04 | Pacira Pharmaceuticals Incorporated | $1,670 | Research payment | In-kind items and services | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXPAREL WHEN ADMINISTERED VIA | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $1,028 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2019 |
| 2019-11-02 | HEARTFLOW, INC. | $26,327 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-11-01 | HEARTFLOW, INC. | $90,343 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-11-01 | HEARTFLOW, INC. | $28,290 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-11-01 | HEARTFLOW, INC. | $15,440 | Research payment | Cash or cash equivalent | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care | 2019 | |
| 2019-10-31 | Agios Pharmaceuticals, Inc. | $2,952 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-10-30 | Merck Sharp & Dohme LLC | $34,886 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | Randomized, Phase II Study of MK-3475 versus Chemotherapy in Patients with Advanced Melanoma | 2019 |
| 2019-10-30 | Merck Sharp & Dohme LLC | $2,680 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-30 | Cardiovascular Systems Inc. | $287 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-30 | Bolton Medical Inc | $250 | Research payment | Cash or cash equivalent | Relay PAS Device | Relay PAS | 2019 |
| 2019-10-29 | AstraZeneca Pharmaceuticals LP | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 | |
| 2019-10-28 | Amicus Therapeutics, Inc. | $11,457 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2019 | |
| 2019-10-28 | Davol Inc. | $482 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-10-28 | Davol Inc. | $482 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-10-28 | Davol Inc. | $215 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-10-28 | Davol Inc. | $215 | Charitable Contribution | In-kind items and services | 2019 | ||
| 2019-10-28 | EMD Millipore Corporation | $194 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-10-28 | EMD Millipore Corporation | $59 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-10-28 | EMD Millipore Corporation | $57 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-10-28 | EMD Millipore Corporation | $52 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-10-28 | EMD Millipore Corporation | $48 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-10-25 | Aesculap Biologics, LLC | $17,991 | Research payment | Cash or cash equivalent | NOVOCART 3D Device, CARTILAGE REPAIR AND REGENERATION | NOVOCART 3D FOR THE TREATMENT OF ARTICULAR CARTILAGE OF THE KNEE N3D | 2019 |
| 2019-10-25 | Merck Sharp & Dohme LLC | $9,808 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-25 | Teva Pharmaceuticals USA, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BENDEKA Drug, Oncology | 2019 | |
| 2019-10-24 | Terumo Medical Corporation | $75,000 | Research payment | Cash or cash equivalent | Glidesheath Device, Lesion Access | SAFE STEMI | 2019 |
| 2019-10-23 | CSL Behring | $1,721,906 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-10-23 | CSL Behring | $512,696 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-10-23 | Merck Sharp & Dohme LLC | $8,549 | Research payment | Cash or cash equivalent | MK-7123 Drug, ONCOLOGY | A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,M | 2019 |
| 2019-10-23 | Smith+Nephew, Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Profore range Device, Core Advanced Wound Care | 2019 | |
| 2019-10-18 | TransMedics, Inc. | $24,464 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | EXPAND HEART CAP | 2019 |
| 2019-10-18 | TransMedics, Inc. | $24,430 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | DCD HEART TRIAL | 2019 |
| 2019-10-18 | TransMedics, Inc. | $4,000 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS LUNG TOP REGISTRY | 2019 |
| 2019-10-18 | W. L. Gore & Associates, Inc. | $300 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-10-16 | Leadiant Biosciences, Inc. | $99,577 | Research payment | Cash or cash equivalent | Revcovi Biological, Immunodeficiency | Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $7,008 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $844 | Research payment | Cash or cash equivalent | MK-7123 Drug, ONCOLOGY | A Phase II Study of Navarixin MK-7123 in Combination with Pembrolizumab MK-3475 in Participants with Selected Advanced,M | 2019 |
| 2019-10-15 | IRONWOOD PHARMACEUTICALS, INC | $30,555 | Research payment | Cash or cash equivalent | IW-3718 | C3718-302 | 2019 |
| 2019-10-15 | PFIZER INC. | $16,456 | Research payment | In-kind items and services | A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFI | 2019 | |
| 2019-10-15 | CSL Behring | $13,000 | Research payment | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | The Safety and Efficacy of Alpha-1 Antitrypsin AAT for the Prevention of GraftVersus-host Disease GVHD in Patients Recei | 2019 |
| 2019-10-15 | Laminate Medical Technologies inc. | $5,475 | Research payment | Cash or cash equivalent | Device, B | A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous | 2019 |
| 2019-10-15 | PFIZER INC. | $2,300 | Research payment | In-kind items and services | A PHASE 1 STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND PHARMACODYNAMICS OF ESCALATING DOSES AND TREATMENT INTENSIFI | 2019 | |
| 2019-10-15 | C. R. Bard, Inc. & Subsidiaries | $442 | Research payment | In-kind items and services | ARCTIC SUN Device, MEDICAL SYSTEMS | INTREPID BMD1111 | 2019 |
| 2019-10-11 | CSL Behring | $2,169,025 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-10-11 | CSL Behring | $852,537 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-10-11 | Dompe US, Inc. | $39,150 | Research payment | Cash or cash equivalent | Corneal macrophage activity in recombinant nerve growth factor therapy, The ability for corneal nerves to thrive followi | 2019 | |
| 2019-10-11 | Ocular Therapeutix, Inc. | $7,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Davol Inc. | $5,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-10-11 | Merck Sharp & Dohme LLC | $2,026 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2019 |
| 2019-10-11 | W. L. Gore & Associates, Inc. | $750 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE EXCLUDER Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto- | 2019 |
| 2019-10-11 | W. L. Gore & Associates, Inc. | $300 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | GORE EXCLUDER Conformable Endoprosthesis | 2019 |
| 2019-10-10 | CSL Behring | $12,045 | Research payment | Cash or cash equivalent | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II | 2019 | |
| 2019-10-09 | Amicus Therapeutics, Inc. | $23,517 | Research payment | Cash or cash equivalent | PROPEL Study - A Study Comparing ATB200/AT2221 With Alglucosidase/Placebo in Adult Subjects With LOPD | 2019 | |
| 2019-10-09 | TransMedics, Inc. | $2,233 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | OCS LUNG TOP REGISTRY | 2019 |
| 2019-10-09 | Stryker Corporation | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $58 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $11 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-08 | CSL Behring | $7,455 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-10-08 | CSL Behring | $2,500 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-10-08 | CSL Behring | $1,900 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-10-08 | IRONWOOD PHARMACEUTICALS, INC | $1,398 | Research payment | Cash or cash equivalent | IW-3718 | C3718-302 | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $79 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-10-07 | Merck Sharp & Dohme LLC | $807 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2019 |
| 2019-10-07 | Merck Sharp & Dohme LLC | $807 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase 3 randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of letermovir | 2019 |
| 2019-10-04 | GENZYME CORPORATION | $5,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DUPIXENT Drug, IMMUNOLOGY | 2019 | |
| 2019-10-03 | Leadiant Biosciences, Inc. | $30,568 | Research payment | Cash or cash equivalent | Revcovi Biological, Immunodeficiency | Monitoring Enzyme Replacement Therapy (Registry Surveillance Study) | 2019 |
| 2019-10-03 | Olympus America Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Olympus EndoTherapy Accessories Device, EndoTherapy Products | 2019 | |
| 2019-10-03 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-10-03 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pha | 2019 |
| 2019-10-02 | Merck Sharp & Dohme LLC | $2,680 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-02 | Boehringer Ingelheim International GmbH | $179 | Research payment | Cash or cash equivalent | JARDIANCE Drug, DIABETES | Empagliflozin and Heart failure (HFrEF) | 2019 |
| 2019-10-02 | Cardiovascular Systems Inc. | $112 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2019 |
| 2019-10-01 | GE HEALTHCARE | $7,500 | Research payment | Cash or cash equivalent | Device, X-RAY | DIGITAL TOMOSYNTHESIS: DETERMINATION OF SENSITIVITY AND RADIATION EXPOSURE COMPARED TO STANDARD COMPUTED TOMOGRAPHY FOR | 2019 |
| 2019-10-01 | Agios Pharmaceuticals, Inc. | $4,508 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-10-01 | CSL Behring | $772 | Research payment | Cash or cash equivalent | Hizentra Biological, Immunology | Comparison of two infusion devices with respect to Pharmacokinetics, safety and tolerability of Hizentra The Hizentra Go | 2019 |
| 2019-09-30 | Agios Pharmaceuticals, Inc. | $2,882 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-09-27 | Bolton Medical Inc | $3,717 | Research payment | Cash or cash equivalent | Relay PAS Device | Relay PAS | 2019 |
| 2019-09-27 | Merck Sharp & Dohme LLC | $776 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-26 | EMD Millipore Corporation | $4,000 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2019 | |
| 2019-09-26 | Agios Pharmaceuticals, Inc. | $680 | Research payment | Cash or cash equivalent | TIBSOVO Drug, ONCOLOGY | STUDY OF AG-120 AND AG-881 IN SUBJECTS WITH LOW GRADE GLIOMA | 2019 |
| 2019-09-25 | Bolton Medical Inc | $2,443 | Research payment | Cash or cash equivalent | Relay PAS Device | Relay PAS | 2019 |
| 2019-09-24 | ConvaTec Inc. | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | FLEXI-SEAL FMS Device, CONTINENCE AND CRITICAL CARE | 2019 | |
| 2019-09-24 | AstraZeneca Pharmaceuticals LP | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LOKELMA Drug, Cardiovascular and Metabolism | 2019 | |
| 2019-09-20 | Merck Sharp & Dohme LLC | $132,942 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Cancers of Mullerian Origin | 2019 |
| 2019-09-20 | Baxter Healthcare | $25,000 | Education | Cash or cash equivalent | Non-Franchise (NOF) - R&D Biological, Fluid Systems | 2019 | |
| 2019-09-20 | Baxter Healthcare | $25,000 | Education | Cash or cash equivalent | Non-Franchise (NOF) - R&D Biological, Fluid Systems | 2019 | |
| 2019-09-20 | W. L. Gore & Associates, Inc. | $8,652 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Evaluation of the GORE TAG TSSB-LSA Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms | 2019 |
| 2019-09-19 | IRONWOOD PHARMACEUTICALS, INC | $848 | Research payment | Cash or cash equivalent | IW-3718 | C3718-302 | 2019 |
| 2019-09-19 | IRONWOOD PHARMACEUTICALS, INC | $750 | Research payment | Cash or cash equivalent | IW-3718 | C3718-302 | 2019 |
| 2019-09-18 | CSL Behring | $1,827,344 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-09-18 | CSL Behring | $596,915 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2019 | |
| 2019-09-18 | Merck Sharp & Dohme LLC | $22,878 | Research payment | Cash or cash equivalent | BRIDION Drug, NEUROSCIENCE | A Phase 4 Double-Blinded, Randomized, Active Comparator-ControlledClinical Trial to Study the Efficacy, Safety, and Phar | 2019 |
| 2019-09-18 | Intuitive Surgical, Inc. | $1,800 | Grant | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-09-18 | Broncus Medical | $1,000 | Consulting Fee | Cash or cash equivalent | 2019 | ||
| 2019-09-18 | AstraZeneca Pharmaceuticals LP | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LYNPARZA Drug, Oncology | 2019 |
The latest 200 records of 973.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Durham, NC, county Durham County, NC, state North Carolina; placed by its city name.
| Measure | Place (city or town) Durham, NC | County Durham County, NC | State North Carolina |
|---|---|---|---|
| Population B01003 | 291,467 | 332,353 | 10,730,404 |
| Population, 2020 census P1 | 283,506 | 324,833 | 10,439,388 |
| Median age B01002 | 35.1 | 36.1 | 39.1 |
| Under 18 B01001 | 20.1% | 20.0% | 21.8% |
| 65 and over B01001 | 13.5% | 14.5% | 17.2% |
| Households B11001 | 126,550 | 141,847 | 4,282,345 |
| Foreign born B05002 | 15.4% | 15.4% | 9.1% |
| Median household income B19013 | $81,619 | $82,316 | $72,388 |
| Median family income B19113 | $110,119 | $109,993 | $90,290 |
| Per capita income B19301 | $49,636 | $49,447 | $41,385 |
| Poverty rate B17001 | 11.7% | 11.5% | 13.0% |
| Unemployment rate B23025 | 3.8% | 3.9% | 4.7% |
| Civilian labor force B23025 | 165,391 | 184,245 | 5,336,863 |
| Mean commute (minutes) B08013 | 22.3 | 22.6 | 25.1 |
| Bachelor's degree or higher B15003 | 57.3% | 55.2% | 35.7% |
| Housing units B25001 | 136,837 | 153,022 | 4,895,668 |
| Owner-occupied B25003 | 52.3% | 55.5% | 66.6% |
| Renters B25003 | 47.7% | 44.5% | 33.4% |
| Median home value B25077 | $392,800 | $389,400 | $288,900 |
| Median gross rent B25064 | $1,508 | $1,508 | $1,228 |
| White, not Hispanic B03002 | 40.3% | 41.7% | 60.0% |
| Black B03002 | 33.2% | 31.8% | 20.0% |
| Hispanic or Latino B03002 | 15.2% | 15.8% | 11.3% |
| Asian B03002 | 5.8% | 5.4% | 3.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.8% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Durham, NC.
Comments